Half-Life Cancer Research Results

Half-Life, Half-Life: Click to Expand ⟱
Source:
Type:
For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream.
In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects.
Scientific Papers found: Click to Expand⟱
2327- 2DG,    2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents
- Review, Var, NA
Glycolysis↓, HK2↓, mt-ROS↑, AMPK↑, PPP↓, NADPH↓, GSH↓, Bax:Bcl2↑, Apoptosis↑, RadioS↑, eff↓, Half-Life↓, other↝, eff↓,
5291- 5-HTP,    Kinetics of l-5-hydroxytryptophan in healthy subjects
- in-vivo, Nor, NA
*Half-Life↝, *BioAv↑,
3972- ACNs,    Recent Research on the Health Benefits of Blueberries and Their Anthocyanins
- Review, AD, NA - Review, Park, NA
*cardioP↑, *neuroP↑, *Inflam↓, *antiOx↓, *GutMicro↑, *Half-Life↑, *LDL↓, *adiP↓, *HDL↑, *CRP↓, *IL1β↓, *Risk↓, *Risk↓, *cognitive↑, *memory↑, *other↑, *BOLD↑, *NO↓, *MDA↓, *GSH↑, *VitC↑, *SOD↑, *GPx↑, *eff↓, *eff↓, *eff↓, *eff↝, *Risk↓,
5469- AF,    Ligand supplementation restores the cancer therapy efficacy of the antirheumatic drug auranofin from serum inactivation
- in-vitro, CRC, HCT116
eff↑, Half-Life↑,
5457- AF,    Clinical pharmacokinetics of oral and injectable gold compounds
- Human, Nor, NA
*BioAv↝, *Dose↝, *Half-Life↑, *BioAv↝, *other↝,
5456- AF,    Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent
- Trial, Nor, NA
*Dose?, *Half-Life↝, *Dose↑, *toxicity↝, *Bacteria↓, *Dose↑,
5455- AF,    Ridaura
- Study, PSA, NA
Dose↝, Half-Life↝,
5470- AF,    Exploring a Therapeutic Gold Mine: The Antifungal Potential of the Gold-Based Antirheumatic Drug Auranofin
- Review, Var, NA
TrxR↓, other↝, IL6↑, IL8↑, NK cell⇅, COX2↓, NOS2↓, NRF2↑, Prx↑, Half-Life↑, Dose↝, ROS↑, NF-kB↓,
5443- AG,    Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers
- Human, Nor, NA
*Dose↝, Half-Life↝, *toxicity↓,
4600- AgNPs,    Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model
- in-vivo, Nor, NA
*Half-Life↝, *toxicity↓, *Dose↑, *other↝, *eff↝, *BioAv↓,
5355- AL,    Mini-review: The health benefits and applications of allicin
- Review, Var, NA
*BioAv↑, *cardioP↑, *hepatoP↑, *RenoP↑, *Half-Life↝, *BioAv↓, *neuroP↑, *cognitive↑, *ROS↓, *lipid-P↓, *DNArepair↑, *ChemoSen↑,
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
1916- AL,    Allicin Bioavailability and Bioequivalence from Garlic Supplements and Garlic Foods
- Review, Nor, NA
*BioAv↝, *eff↓, *BioAv↝, *BioAv↝, *eff↑, *Half-Life∅, *eff↑, *eff↑, *Dose∅, *eff↑,
3443- ALA,    Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention
- Review, Var, NA - Review, AD, NA
*antiOx↑, *ROS↓, *IronCh↑, *cognitive↑, *cardioP↓, AntiCan↑, *neuroP↑, *Inflam↓, *BioAv↓, *AntiAge↑, *Half-Life↓, *BioAv↝, other↝, EGFR↓, Akt↓, ROS↓, TumCCA↑, p27↑, PDH↑, Glycolysis↓, ROS↑, *eff↑, *memory↑, *motorD↑, *GutMicro↑,
3550- ALA,    Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer's Disease?
- Review, AD, NA
*antiOx↑, *Inflam↓, *PGE2↓, *COX2↓, *iNOS↓, *TNF-α↓, *IL1β↓, *IL6↓, *BioAv↓, *Ach↑, *ROS↓, *cognitive↑, *neuroP↑, *BBB↑, *Half-Life↓, *BioAv↑, *Casp3↓, *Casp9↓, *ChAT↑, *cognitive↑, *eff↑, *cAMP↑, *IL2↓, *INF-γ↓, *TNF-α↓, *SIRT1↑, *SOD↑, *GPx↑, *MDA↓, *NRF2↑,
3545- ALA,    Potential therapeutic effects of alpha lipoic acid in memory disorders
- Review, AD, NA
*neuroP↑, *Inflam↓, *VCAM-1↓, *5HT↑, *memory↑, *BioAv↝, *Half-Life↓, *NF-kB↓, *antiOx↑, *IronCh↑, *ROS↓, *ATP↑, *ChAT↑, *Ach↑, *cognitive↑, *lipid-P↓, *VitC↑, *VitE↑, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, *Aβ↓,
297- ALA,    Insights on the Use of α-Lipoic Acid for Therapeutic Purposes
- Review, BC, SkBr3 - Review, neuroblastoma, SK-N-SH - Review, AD, NA
PDH↑, TumCG↓, ROS↑, AMPK↑, EGR4↓, Half-Life↓, BioAv↝, *GSH↑, *IronCh↑, *ROS↓, *antiOx↑, *neuroP↑, *Ach↑, *lipid-P↓, *IL1β↓, *IL6↓, TumCP↓, FDG↓, Apoptosis↑, AMPK↑, mTOR↓, EGFR↓, TumCI↓, TumCMig↓, *memory↑, *BioAv↑, *BioAv↝, *other↓, *other↝, *Half-Life↓, *BioAv↑, *ChAT↑, *GlucoseCon↑,
5322- ALC,    Comparison of pharmacokinetics of L-carnitine, Acetyl-L-carnitine and Propionyl-Lcarnitine after single oral administration of L-carnitine in healthy volunteers
- Human, Nor, NA
*Half-Life↝,
1152- Api,    Does Oral Apigenin Have Real Potential for a Therapeutic Effect in the Context of Human Gastrointestinal and Other Cancers?
- Analysis, Nor, NA
*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, eff↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,
1548- Api,    A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms
- Review, Colon, NA
*BioAv↓, *Half-Life∅, selectivity↑, *toxicity↓, Wnt/(β-catenin)↓, P53↑, P21↑, PI3K↓, Akt↓, mTOR↓, TumCCA↑, TumCI↓, TumCMig↓, STAT3↓, PKM2↓, EMT↓, cl‑PARP↑, Casp3↑, Bax:Bcl2↑, VEGF↓, Hif1a↓, Dose∅, GLUT1↓, GlucoseCon↓,
1542- Api,    Bioavailability of Apigenin from Apiin-Rich Parsley in Humans
- Human, NA, NA
*BioAv?, *Half-Life?,
1537- Api,    Apigenin as Tumor Suppressor in Cancers: Biotherapeutic Activity, Nanodelivery, and Mechanisms With Emphasis on Pancreatic Cancer
- Review, PC, NA
TumCP↓, TumCCA↑, Apoptosis↑, MMPs↓, Akt↓, *BioAv↑, *BioAv↓, Half-Life∅, Hif1a↓, GLUT1↓, VEGF↓, ChemoSen↑, ROS↑, Bcl-2↓, Bcl-xL↓, BAX↑, BIM↑,
3382- ART/DHA,    Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
- Review, Var, NA
AntiCan↑, toxicity↑, Ferroptosis↑, ROS↑, TumCCA↑, BioAv↝, eff↝, Half-Life↓, Ferritin↓, GPx4↓, NADPH↓, GSH↓, BAX↑, Cyt‑c↑, cl‑Casp3↑, VEGF↓, IL8↓, COX2↓, MMP9↓, E-cadherin↑, MMP2↓, NF-kB↓, p16↑, CDK4↓, cycD1/CCND1↓, p62↓, LC3II↑, EMT↓, CSCs↓, Wnt↓, β-catenin/ZEB1↓, uPA↓, TumAuto↑, angioG↓, ChemoSen↑,
3391- ART/DHA,    Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug
- Review, Var, NA
TumCP↓, TumMeta↓, angioG↓, TumVol↓, BioAv↓, Half-Life↓, BioAv↑, eff↑, eff↓, ROS↑, selectivity↑, TumCCA↑, survivin↓, BAX↑, Casp3↓, Casp8↑, Casp9↑, CDC25↓, CycB/CCNB1↓, NF-kB↓, cycD1/CCND1↓, cycE/CCNE↓, E2Fs↓, P21↑, p27↑, ADP:ATP↑, MDM2↓, VEGF↓, IL8↓, COX2↓, MMP9↓, ER Stress↓, cMyc↓, GRP78/BiP↑, DNAdam↑, AP-1↓, MMP2↓, PKCδ↓, Raf↓, ERK↓, JNK↓, PCNA↓, CDK2↓, CDK4↓, TOP2↓, uPA↓, MMP7↓, TIMP2↑, Cdc42↑, E-cadherin↑,
5383- ART/DHA,    Artesunate is a drug used to treat severe malaria.
- Review, Var, NA
Half-Life?,
2569- ART/DHA,    A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction
- Human, Nor, NA
*Half-Life↝, BioAv↝, *Half-Life↓, BioAv↑, *Dose↝,
2570- ART/DHA,    Discovery, mechanisms of action and combination therapy of artemisinin
- Review, Nor, NA
*BioAv↓, *Half-Life↓, *toxicity↓, *ROS↑, GSH↓, selectivity↑,
5412- ASA,    Clinical Pharmacology of Aspirin
- Review, NA, NA
*COX1↓, *COX2↓, *cardioP↑, *BioAv↑, *BioAv↝, *Half-Life↓, Risk↓, *other↑, *AntiAg↑,
5400- ASA,    Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention
- Review, Nor, NA
Risk↓, *Inflam↓, *COX1↓, *AntiAg↑, *Half-Life↓, *BioAv↑,
5402- ASA,    Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity
- Review, Var, NA
COX1↓, TumMeta↓, *Half-Life↓, *COX2↓, *TXA2↓,
5393- Ash,    Studies on oral bioavailability and first-pass metabolism of withaferin A in rats using LC-MS/MS and Q-TRAP
- in-vivo, Nor, NA
*BioAv↝, *other↝, *Half-Life↓,
3155- Ash,    Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera
- Review, Var, NA
Half-Life↝, Inflam↓, antiOx↓, angioG↓, ROS↑, BAX↑, Bak↑, E6↓, E7↓, P53↑, Casp3↑, cl‑PARP↑, STAT3↓, eff↑, HSP90↓, TGF-β↓, TNF-α↓, EMT↑, mTOR↓, NOTCH1↓, p‑Akt↓, NF-kB↓, Dose↝,
3166- Ash,    Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives
- Review, Var, NA
*p‑PPARγ↓, *cardioP↑, *AMPK↑, *BioAv↝, *Half-Life↝, *Half-Life↝, *Dose↑, *chemoPv↑, IL6↓, STAT3↓, ROS↓, OXPHOS↓, PCNA↓, LDH↓, AMPK↑, TumCCA↑, NOTCH3↓, Akt↓, Bcl-2↓, Casp3↑, Apoptosis↑, eff↑, NF-kB↓, CSCs↓, HSP90↓, PI3K↓, FOXO3↑, β-catenin/ZEB1↓, N-cadherin↓, EMT↓, FASN↓, ACLY↓, ROS↑, NRF2↑, HO-1↑, NQO1↑, JNK↑, mTOR↓, neuroP↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL18↓, RadioS↑, eff↑,
5423- ASTX,    Pharmacokinetic Profile of Astaxanthin Nanoemulsion Using HPLC (High-Performance Liquid Chromatography) With Oral Routes
- in-vivo, Nor, NA
*BioAv↓, *antiOx↑, *BioAv↑, *Half-Life↝,
5373- ATO,    arsenic trioxide
- Human, APL, NA
Half-Life↝,
5445- ATV,    Atorvastatin
- NA, Nor, NA
*cardioP↑, *LDL↓, HMG-CoA↓, Half-Life↝, BioAv↓, Dose↝,
5508- Ba,    Neuroprotective effects of baicalin and baicalein on the central nervous system and the underlying mechanisms
- Review, Stroke, NA - Review, Park, NA - Review, AD, NA
*neuroP↑, *antiOx↑, *Inflam↓, *BioAv↝, *BioAv↑, *Half-Life↝, *TLR4↓, *NF-kB↓, *iNOS↓, *COX2↓, *TNF-α↓, *12LOX↓, *NLRP3↓, *ROS↓, *IL1β↓, *IL6↓, *GSK‐3β↓, *NRF2↑, *BBB↑, *SOD↑, *GPx↑, *MDA↓,
5500- Ba,    Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study
- Trial, Nor, NA
*toxicity↓, *BioAv↑, *Half-Life↝, *Dose↝,
5249- Ba,  BA,    Baicalein and baicalin in cancer therapy: Multifaceted mechanisms, preclinical evidence, and translational challenges
- Review, Var, NA
Apoptosis↑, Inflam↓, TumCCA↑, ChemoSen↑, RadioS↑, TumCG↓, toxicity↓, BioAv↓, Half-Life↓,
5543- BBM,    Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo
- in-vivo, Lung, B16-F10 - vitro+vivo, Lung, A549 - in-vitro, BC, MDA-MB-231
BioAv↓, Half-Life↓, eff↑, TumMeta↓, TumCP↓, TumCG↓, Apoptosis↑, TumCCA↑, MMP2↓, MMP9↓, VEGF↓, Bcl-2↓, eff↑, EPR↑,
2671- BBR,    Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I: A Mechanism for the Action of Berberine to Activate AMP-Activated Protein Kinase and Improve Insulin Action
- in-vivo, Diabetic, NA
*BioAv↓, *Half-Life↝, *OCR↓, *AMPK↑,
2672- BBR,    The anti-aging mechanism of Berberine associated with metabolic control
- Review, Var, NA
*BioAv↝, *BioAv↝, *BioAv↝, *Half-Life↓,
2673- BBR,    Therapeutic potential and recent delivery systems of berberine: A wonder molecule
- Review, Var, NA
*BioAv↓, *Half-Life↓, *neuroP↑, BBB↑, toxicity↓,
3680- BBR,    Network pharmacology reveals that Berberine may function against Alzheimer’s disease via the AKT signaling pathway
- in-vivo, AD, NA
*Akt↑, *neuroP↑, *p‑ERK↑, *Aβ↓, *Inflam↓, *ROS↓, *BioAv↑, *BBB↑, *Half-Life↝, *memory↑, *cognitive↑, *HSP90↑, *APP↓, *mTOR↓, *P70S6K↓, *CD31↑, *VEGF↑, *N-cadherin↑, *Apoptosis↓,
5634- BCA,    Molecular Mechanisms of Biochanin A in AML Cells: Apoptosis Induction and Pathway-Specific Regulation in U937 and THP-1
- in-vitro, AML, U937 - in-vitro, AML, THP1
Apoptosis↑, Casp7↑, PARP1↑, Bcl-2↓, Myc↓, CHOP↑, P21↑, p62↑, TumCCA↑, TXNIP↑, ROS↑, *antiOx↑, *Inflam↓, *neuroP↑, AntiCan↑, TumCP↓, angioG↓, TumMeta↓, VEGF↓, MMPs↓, tumCV↓, DNAdam↑, CHOP↑, cMyc↓, BioAv↓, Half-Life↓, BioAv↑,
5589- BetA,    Advancements in Betulinic Acid-Loaded Nanoformulations for Enhanced Anti-Tumor Therapy
- Review, Var, NA
BioAv↓, toxicity↝, BioAv↑, Half-Life↑,
5588- BetA,    Therapeutic applications of betulinic acid nanoformulations
- Review, Var, NA
BioAv↓, Half-Life↓, BioAv↑, Half-Life↑,
2716- BetA,    Cellular and molecular mechanisms underlying the potential of betulinic acid in cancer prevention and treatment
- Review, Var, NA
AntiCan↑, TumCD↑, TumCCA↑, ROS↑, NF-kB↓, Bcl-2↓, Half-Life↝, GLUT1↓, VEGF↓, PDK1↓,
5518- BEV,  Chemo,    Bevacizumab
- Review, Var, NA - Review, AMD, NA
Dose↝, other↑, VEGF↓, eff↑, Half-Life↑,
5597- Bical,    Bicalutamide: clinical pharmacokinetics and metabolism
- Review, Pca, NA
Dose↝, BioAv↑, Half-Life↑, CYP3A4↓, PSA↓,

Showing Research Papers: 1 to 50 of 167
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 167

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 4,   HO-1↑, 1,   NQO1↑, 1,   NRF2↑, 2,   OXPHOS↓, 1,   Prx↑, 1,   ROS↓, 2,   ROS↑, 11,   mt-ROS↑, 1,   TrxR↓, 1,  

Metal & Cofactor Biology ⓘ

Ferritin↓, 1,  

Mitochondria & Bioenergetics ⓘ

ADP:ATP↑, 1,   CDC25↓, 1,   Raf↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACLY↓, 1,   AMPK↑, 4,   cMyc↓, 2,   CYP3A4↓, 2,   FASN↓, 1,   FDG↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   HK2↓, 1,   HMG-CoA↓, 1,   LDH↓, 1,   NADPH↓, 2,   PDH↑, 2,   PDK1↓, 1,   PKM2↓, 1,   PPP↓, 1,  

Cell Death ⓘ

Akt↓, 4,   p‑Akt↓, 1,   Apoptosis↑, 7,   Bak↑, 1,   BAX↑, 4,   Bax:Bcl2↑, 2,   Bcl-2↓, 6,   Bcl-xL↓, 1,   BIM↑, 1,   Casp12↑, 1,   Casp3↓, 1,   Casp3↑, 4,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp8↑, 2,   Casp9↑, 2,   Cyt‑c↑, 2,   Fas↑, 1,   Ferroptosis↑, 1,   JNK↓, 1,   JNK↑, 1,   MDM2↓, 1,   Myc↓, 1,   p27↑, 2,   p38↑, 1,   survivin↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,   other↝, 3,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   ER Stress↓, 1,   GRP78/BiP↑, 1,   HSP90↓, 2,  

Autophagy & Lysosomes ⓘ

LC3II↑, 1,   p62↓, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   DNAdam↑, 2,   p16↑, 1,   P53↑, 3,   cl‑PARP↑, 2,   PARP1↑, 1,   PCNA↓, 2,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↓, 2,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 1,   E2Fs↓, 1,   P21↑, 4,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

CSCs↓, 2,   EMT↓, 3,   EMT↑, 1,   ERK↓, 1,   FOXO3↑, 1,   mTOR↓, 4,   NOTCH1↓, 1,   NOTCH3↓, 1,   PI3K↓, 2,   STAT3↓, 4,   TOP2↓, 1,   TumCG↓, 3,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

AP-1↓, 1,   Cdc42↑, 1,   E-cadherin↑, 2,   p‑FAK↓, 1,   MMP2↓, 3,   MMP7↓, 1,   MMP9↓, 3,   MMPs↓, 2,   N-cadherin↓, 1,   PKCδ↓, 1,   TGF-β↓, 1,   TIMP2↑, 1,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 5,   TumMeta↓, 4,   TXNIP↑, 1,   uPA↓, 2,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 4,   EGFR↓, 2,   EGR4↓, 1,   EPR↑, 1,   Hif1a↓, 3,   VEGF↓, 9,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT1↓, 3,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 3,   IL6↓, 1,   IL6↑, 1,   IL8↓, 3,   IL8↑, 1,   Inflam↓, 2,   NF-kB↓, 6,   NK cell⇅, 1,   PSA↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 7,   BioAv↑, 6,   BioAv↝, 3,   ChemoSen↑, 3,   CYP1A2↓, 1,   CYP2C9↓, 1,   Dose↝, 6,   Dose∅, 2,   eff↓, 3,   eff↑, 9,   eff↝, 1,   Half-Life?, 1,   Half-Life↓, 8,   Half-Life↑, 6,   Half-Life↝, 6,   Half-Life∅, 2,   RadioS↑, 3,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

E6↓, 1,   E7↓, 1,   EGFR↓, 2,   Ferritin↓, 1,   IL6↓, 1,   IL6↑, 1,   LDH↓, 1,   Myc↓, 1,   NOS2↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 5,   chemoP↑, 1,   neuroP↑, 1,   Risk↓, 2,   toxicity↓, 2,   toxicity↑, 1,   toxicity↝, 1,   TumVol↓, 1,  
Total Targets: 175

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 9,   Catalase↑, 1,   GPx↑, 4,   GSH↑, 4,   GSTs↑, 1,   HDL↑, 1,   Keap1↓, 1,   lipid-P↓, 4,   MDA↓, 4,   MPO↓, 1,   NRF2↑, 3,   ROS↓, 9,   ROS↑, 1,   SOD↑, 5,   TBARS↓, 1,   VitC↑, 2,   VitE↑, 1,  

Metal & Cofactor Biology ⓘ

IronCh↑, 3,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   adiP↓, 1,   ALAT↓, 1,   AMPK↑, 2,   cAMP↑, 1,   GlucoseCon↑, 1,   H2S↑, 1,   LDH↓, 2,   LDL↓, 2,   p‑PPARγ↓, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 1,   Akt↑, 1,   Apoptosis↓, 1,   Casp3↓, 1,   Casp9↓, 1,   iNOS↓, 3,  

Transcription & Epigenetics ⓘ

Ach↑, 3,   other↓, 1,   other↑, 3,   other↝, 4,  

Protein Folding & ER Stress ⓘ

HSP90↑, 1,  

DNA Damage & Repair ⓘ

DNArepair↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↑, 1,   GSK‐3β↓, 1,   mTOR↓, 1,   P70S6K↓, 1,   PI3K↓, 1,  

Migration ⓘ

AntiAg↑, 2,   APP↓, 1,   CD31↑, 1,   N-cadherin↑, 1,   VCAM-1↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 2,   TXA2↓, 1,   VEGF↑, 1,  

Barriers & Transport ⓘ

BBB↑, 4,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 2,   COX2↓, 5,   CRP↓, 1,   IL18↓, 1,   IL1β↓, 5,   IL2↓, 1,   IL6↓, 5,   IL8↓, 1,   INF-γ↓, 1,   Inflam↓, 9,   NF-kB↓, 3,   PGE2↓, 2,   TLR4↓, 1,   TNF-α↓, 5,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   ChAT↑, 3,  

Protein Aggregation ⓘ

Aβ↓, 2,   NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv?, 1,   BioAv↓, 12,   BioAv↑, 12,   BioAv↝, 15,   ChemoSen↑, 1,   Dose?, 1,   Dose↑, 4,   Dose↝, 4,   Dose∅, 1,   eff↓, 4,   eff↑, 7,   eff↝, 2,   Half-Life?, 1,   Half-Life↓, 12,   Half-Life↑, 2,   Half-Life↝, 14,   Half-Life∅, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   BP↓, 1,   creat↓, 1,   CRP↓, 1,   GutMicro↑, 3,   IL6↓, 5,   LDH↓, 2,  

Functional Outcomes ⓘ

AntiAge↑, 1,   BOLD↑, 1,   cardioP↓, 1,   cardioP↑, 6,   chemoPv↑, 1,   cognitive↑, 8,   hepatoP↑, 2,   memory↑, 6,   motorD↑, 1,   neuroP↑, 12,   RenoP↑, 1,   Risk↓, 3,   toxicity↓, 5,   toxicity↝, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 1,  
Total Targets: 116

Scientific Paper Hit Count for: Half-Life, Half-Life
7 Resveratrol
6 Boron
6 chitosan
6 Silymarin (Milk Thistle) silibinin
5 Auranofin
5 Artemisinin
5 Capsaicin
5 Pterostilbene
4 Alpha-Lipoic-Acid
4 Apigenin (mainly Parsley)
4 Aspirin -acetylsalicylic acid
4 Berberine
4 Curcumin
4 Chlorogenic acid
4 Sulforaphane (mainly Broccoli)
4 Shikonin
4 Selenite (Sodium)
3 Allicin (mainly Garlic)
3 Ashwagandha(Withaferin A)
3 Baicalein
3 Betulinic acid
3 Propolis -bee glue
3 EGCG (Epigallocatechin Gallate)
3 Fisetin
3 Piperlongumine
3 Urolithin
2 borneol
2 Boswellia (frankincense)
2 Disulfiram
2 Ellagic acid
2 Honokiol
2 HydroxyTyrosol
2 Luteolin
2 Lycopene
2 Metformin
2 Phenethyl isothiocyanate
2 Quercetin
2 Rosmarinic acid
2 Thymoquinone
1 2-DeoxyGlucose
1 5-Hydroxytryptophan
1 Anthocyanins
1 Astragalus
1 Silver-NanoParticles
1 Acetyl-l-carnitine
1 Astaxanthin
1 Arsenic trioxide
1 Atorvastatin
1 Baicalin
1 Berbamine
1 Biochanin A
1 Bevacizumab (brand Avastin)
1 Chemotherapy
1 Bicalutamide
1 Bromelain
1 Vitamin D3
1 urea
1 Carvacrol
1 Catechins
1 Cannabichromene
1 cetuximab
1 Chocolate
1 Chrysin
1 Dichloroacetate
1 Copper and Cu NanoParticles
1 Ferulic acid
1 Hydrogen Gas
1 Huperzine A/Huperzia serrata
1 itraconazole
1 Methylene blue
1 Methylsulfonylmethane
1 Naringin
1 Niclosamide (Niclocide)
1 Oleuropein
1 Phenylbutyrate
1 Phosphatidylserine
1 immunotherapy
1 SonoDynamic Therapy UltraSound
1 Radiotherapy/Radiation
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Vitamin C (Ascorbic Acid)
1 Vitamin E
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1109  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page